Free Newsletter
Nanoparticle programs advance the science of small
Researchers at MIT are advancing their work on nanoparticles that mimic blood platelets in order to deliver chemotherapies directly to tumors or for cancer imaging. The nanoparticles are designed to slip through tumor blood vessels so they can cluster in the tumor and be identified with imaging technology. A team of scientists are using a five-year, $4.3 million grant National Cancer Institute grant for their work.
The program is somewhat similar to a new project at Johns Hopkins which has developed nanoparticles that mimic viruses so they can slip through layers of mucus. During experiments with these coated particles, the researchers also discovered that mucus layers have much larger pores than previously thought, providing a doorway that should allow larger and longer-acting doses of medicine to reach protected tissue.
- here's the UPI report on the MIT project
- and here's the report from Johns Hopkins
ALSO: A novel approach to synthesizing nanowires allows their direct integration with microelectronic systems for the first time, as well as their ability to act as highly sensitive biomolecule detectors that could advance biological diagnostic applications, according to a report in Nature. Not only can the nanowires detect as few as 1000 individual molecules in a cubic millimeter, they can do it without any added fluorescent or radioactive probes. Report
Related Articles:
Nanoparticles used to destroy tumors. Report
FDA gathers expert advice on bionanotechnology. Report
Nanotech grows more common in drug dev research. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: